Please read Dr. Mahone’s article in the American Journal of Drug and Alcohol Abuse titled, “Opioid use disorder treatment and the role of New Jersey Medicaid policy changes: perspectives of office-based buprenorphine providers.“
In the US, seventy percent of drug-related deaths are attributed to opioids. In response to the ongoing opioid crisis, New Jersey’s (NJ) Medicaid program implemented the MATrx model to increase treatment access for Medicaid participants with opioid use disorder (OUD). The model’s goals include increasing the number of office-based treatment providers, enhancing Medicaid reimbursement for certain treatment services, and elimination of prior authorizations for OUD medications. To read the full article.
Opioid use disorder treatment and the role of New Jersey Medicaid policy changes: perspectives of office-based buprenorphine providers. Mahone A, Enich M, Treitler P, Lloyd J, Crystal S. Am J Drug Alcohol Abuse. 2023 Jul 28:1-12. PMID: 37506336 DOI: 1080/00952990.2023.2234075